Browse Articles

Discover research articles across all indexed journals

Bioinspired (Glyco)Polypeptides for Ice‐Control and Cell Cryopreservation

Advanced Materials Liang Yuan, Xiaowen Zhang, Lixia Ren et al. Jun 11, 2026 DOI: 10.1002/adma.73464

ABSTRACT Cryopreservation is a powerful technology providing fundamental support for basic biomedical research and clinical translation. Currently, cryoprotectants are commonly incorporated during the cryopreservation of cells to preserve their phenotypes and post‐thaw functionality. However, existing cryoprotective strategies still face crucial challenges in developing highly efficient and biocompatible approaches for storing various types of cells. Inspired by antifreeze (glycol)proteins, which are endogenous in antifreeze or freeze‐tolerant organisms for survival under subzero conditions, (glyco)polypeptides and analogues are developed with ice‐controlling properties and cryoprotective effects to maintain cellular viability and function after cryopreservation. The protein‐mimetic structures endow (glyco)polypeptides with advantages of biocompatibility, chemical structural diversity, multiscale tunability, and potential for economically large‐scale preparation. This review summarizes the synthesis, secondary structures, and self‐assembly behaviors of these (glyco)polypeptides, serving as a valuable bridge connecting polymer architectures to their applications as macromolecular cryoprotectants. The roles of (glyco)polypeptides are emphasized, including their activities and underlying protective mechanisms in ice nucleation, ice shaping, and ice recrystallization inhibition, as well as their cryopreservation performance for cells. Finally, in view of the requirement for a precise understanding of structure–property relationships, the prospects of multifunctional (glyco)polypeptides are discussed, with an outlook on the integration of machine learning.

Autonomous pathfinding for underactuated AUVs using FDHNN

Scientific Reports Mingzhi Chen, Hongfei Li, Liming Feng et al. Jun 11, 2026 DOI: 10.1038/s41598-026-56020-8

Microsoft upgrades controversial quantum chip — researchers are still sceptical

Nature Davide Castelvecchi Jun 11, 2026 DOI: 10.1038/d41586-026-01788-y

Assessing the usefulness of digital contact tracing using real-world contact data

Scientific Reports Chuan Li, Vincent Gauthier, Miguel Nunez-del-Prado et al. Jun 11, 2026 DOI: 10.1038/s41598-026-51160-3

Theoretical and experimental investigation of NiFe2O4 and CaMnO3 nanoparticles to study their structural, magnetic, and polarization properties for energy-related applications

Scientific Reports Hassan Ali, Samar Fatima, Tanvir Hussain et al. Jun 11, 2026 DOI: 10.1038/s41598-026-53021-5

Sustainable removal of Acid Black 172 from wastewater using Lantana camara derived biochar insights from adsorption and statistical physics modeling

Scientific Reports Mohammod Hafizur Rahman, Ganesh Jethave, Umesh Fegade et al. Jun 11, 2026 DOI: 10.1038/s41598-026-57437-x

Swin-DRNet: A robust transformer framework for diabetic retinopathy screening under heterogeneous imaging conditions

Scientific Reports Damodharan Palaniappan, N R Ram Mohan, T Premavathi et al. Jun 11, 2026 DOI: 10.1038/s41598-026-57053-9

Sustainable ionic liquid-assisted cloud point extraction for enrichment of trace copper(II) in water and food samples prior to spectrophotometric determination

Scientific Reports Nagwa M. A. El-Bialy, Ayman A. Gouda, El-Sayed I. A. Ghaith et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56689-x

Abstract This work introduces a novel, cost-effective, and sustainable ionic liquid–assisted cloud point extraction (IL-CPE) technique for the enrichment and spectrophotometric quantification of trace copper(II) at 436 nm. The method employs the complexation of Cu(II) with (Z)-4-bromo-2-(((2-hydroxyphenyl)imino)methyl)phenol at pH 6.5, succeeded by extraction with 1-butyl-3-methylimidazolium hexafluorophosphate and Triton X-114. Under optimal circumstances, the approach exhibited remarkable linearity (2.0–300 µg L⁻¹, R 2  = 0.9997), substantial sensitivity with a preconcentration and enrichment factors 100 and 12.5, respectively, and a minimal detection limit of 0.6 µg L⁻¹. Precision and reliability of the novel IL-CPE method was validated by low relative standard deviation for 100 and 200 µg L⁻¹ ( n  = 10) was 1.6% and 2.0%, respectively, and accuracy was substantiated by the use of certified reference materials and actual environmental samples, encompassing water and food matrices. Moreover, the method’s environmental effect was meticulously assessed utilizing several Green Analytical Chemistry metrics (AGREE, AGREEprep, ComplexMoGAPI, AGSA) and practical indices (BAGI, CACI). The evaluation via the RGB algorithm and Carbon Footprint Reduction Index (CaFRI) verifies that this method is a sustainable, eco-friendly, and very dependable option for regular trace metal detection.

Phase 3 clinical trial of the combination of erlotinib plus ramucirumab compared with osimertinib in untreated advanced or recurrent non-small cell lung cancer with EGFR L858R mutation: The REVOL858R trial (WJOG14420L).

Journal of Clinical Oncology Naoki Haratake, Hidetoshi Hayashi, Kazuya Tsubouchi et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba8518

LBA8518 Background: Among common EGFR-mutant NSCLC, L858R mutation is suggested to be less sensitive to EGFR-TKIs and associated with poorer prognosis than ex 19 del. REVOL858R is the first randomized phase III trial conducted exclusively in patients with advanced/recurrent EGFR L858R–mutant NSCLC, comparing a treatment strategy of erlotinib plus ramucirumab (E+RAM) followed by osimertinib (OSI) upon detection of acquired T790M with first-line OSI monotherapy. Methods: Eligible patients were treatment-naive adults (≥20 years) with advanced/recurrent EGFR L858R–positive NSCLC and ECOG PS 0–1. Patients were randomized 1:1, stratified by clinical stage (IIIB/IIIC/IV vs postoperative recurrence), sex, and baseline brain metastasis (BM). Patients received OSI 80 mg once daily (Arm A) or E+RAM (E 150 mg once daily plus RAM 10 mg/kg every 2 weeks; Arm B). In Arm B, tumor rebiopsy or liquid biopsy at termination of E+RAM was mandated; patients with detected T790M subsequently received OSI, whereas those without T790M discontinued protocol treatment. The primary endpoint, time to failure of strategy (TFS), was defined as time from randomization to disease progression or death during OSI, or during the primary treatment when OSI was not administered (in Arm B). Results: Overall, 232 patients were randomized (Arm A n=116; Arm B n=116). Baseline characteristics were generally well balanced between the two arms. In the full analysis set, median TFS was 14.8 months in Arm A and 16.6 months in Arm B (HR 1.03; 95% CI 0.78–1.38; log-rank p=0.49). Key secondary endpoints and selected prespecified subgroup analyses of TFS are summarized in Table. The most common AEs (any grade) were diarrhea (41% vs 54%) and acneiform rash (30% vs 71%) in Arm A vs Arm B. Hypertension and proteinuria were observed in 39% and 18% of patients in Arm B, respectively. Interstitial lung disease occurred in 12 patients (10%) in Arm A, and 2 patients (2%) in Arm B. AEs leading to discontinuation of protocol treatment occurred in 21% vs 36% of patients (Arm A vs Arm B). Conclusions: A planned E+RAM-to-OSI strategy did not improve TFS compared with upfront OSI in EGFR L858R–mutated NSCLC. Safety findings were consistent with known profiles, with higher discontinuation for tolerability in the strategy arm. Trial information: jRCTs051200142. Clinical trial information: 051200142. Key secondary endpoints. Key secondary endpoint, median (months) Arm A (OSI) Arm B (E+RAM) HR (95% CI) OS 44.0 (31.1-NR) 38.4 (33.3-NR) 0.98 (0.66-1.45) 3-y OS (%) 56.1% 57.2% – ORR (%) 73.2% 66.3% – PFS1 14.8 14.9 1.08 (0.81-1.44) PFS2 23.8 25.1 0.96 (0.70-1.33) Time to treatment failure 12.6 11.2 1.34 (1.02-1.77) Key prespecified TFS subgroups <65 years / ≥65 years 18.4 / 14.8 21.2 / 16.0 0.90 (0.40-1.99) / 1.06 (0.78-1.45) With / Without baseline BM 11.8 / 19.2 14.7 / 17.8 0.81 (0.49-1.34) / 1.11 (0.79-1.57)

Electron ptychography reveals correlated lattice vibrations at atomic resolution

Nature Communications Anton Gladyshev, Benedikt Haas, Thomas C. Pekin et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74135-4

Abstract Electron Ptychography is a computational imaging technique capable of performing phase retrieval at atomic resolution. Here we introduce the CAVIAR framework (Correlated Atomic Vibration Imaging with sub-Angstrom Resolution) that reveals spatial correlations in atomic displacements at the atomic scale. Using realistically simulated data for a symmetric Σ 9 grain boundary in silicon and experimental data of a hexagonal boron nitride bicrystal, we observe correlations between atomic movements in the range of 10-20 pm at room temperature in agreement with our expectation. From only the atomic masses and temperature as input, we obtain frequencies of the longitudinal and transverse acoustic and optic phonons from just a few nm 3 volume, in agreement with inelastic neutron scattering. This ability to spatially resolve correlated atomic motion distinguishes CAVIAR and positions it as a complementary tool to vibrational electron energy loss spectroscopy for exploring atom dynamics at the finest scale.

Antioxidant, antimicrobial, and AMPA receptor modulatory activities of selected medicinal plant extracts reveal multitarget pharmacological potential

Scientific Reports Mohammad Qneibi, Belal Rahhal, Nidal Jaradat et al. Jun 10, 2026 DOI: 10.1038/s41598-026-51456-4

From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia

Journal of Clinical Oncology Daniel H. Wiseman, Kiran Batta Jun 10, 2026 DOI: 10.1200/jco-26-00635

PIP2 activation of the cardiac IKs potassium channel

Nature Communications Lu Zhao, Xianjin Xu, Chenxi Cui et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74123-8

Hybrid and advanced convolution techniques for highly accurate, reliable and automated ECG classification

Scientific Reports R. Gokul, Yaswanth Sree Penumalli, Chalamala Ranjith et al. Jun 10, 2026 DOI: 10.1038/s41598-026-55382-3

Abstract Cardiac arrhythmias are a leading cause of cardiovascular mortality worldwide, and auto- mated analysis of electrocardiogram (ECG) recordings is an unmet clinical need. This paper introduces a hybrid 1D Convolutional Neural Network (CNN) architecture for automated ECG heartbeat classification that captures both multi-scale morphological and long-range temporal dependencies. The architecture combines Dynamic Kernel Switching (DKS) with adaptive gating over kernel sizes {3 , 5 , 7}, a Self-Attention module, and Dilated Convolutions at dilation rates 2 and 4. For low-power edge deployment on Neural Processing Units (NPUs) and FPGA/ASIC platforms, three quantization paths are evaluated: (1) Dynamic Post-Training Quantization (PTQ) with INT8 weights and FP32 I/O, (2) Full-Integer PTQ with INT8 weights and activations, and (3) Quantization-Aware Training (QAT). With a corrected stratified 72/8/20 train/validation/test protocol, focal loss ( γ  = 2 . 0), AdamW optimization and cosine learning rate decay, the proposed model achieves 98.99% test accuracy and a macro F1-score of 0.9484 on the MIT-BIH Arrhythmia Database (16,219 held-out test beats, five AAMI classes). Five-fold stratified cross-validation confirms statistical robustness: 98 . 93% ± 0 . 10% accuracy with 95% confidence interval [98.84%, 99.02%]. A comprehensive seven-variant ablation study covering Self-Attention, CBAM, CSA, and SimSA demonstrates that the proposed DKS + Self-Attention combination outperforms all alternatives. Generalization is further validated on five independently withheld MIT-BIH patient recordings (10,444 beats), achieving 92.86% accuracy and macro F1 of 0.8219. The model comprises only 331,733 parameters and reduces to ≈0 . 32 MB under Dynamic PTQ, enabling direct TFLite/INT8 conversion for RTL-level FPGA deployment.

Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT-III): A multicenter, randomized, open-label, phase 3 trial.

Journal of Clinical Oncology Zhangfa Song, Bingjun Bai, Min Chen et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba3515

LBA3515 Background: Total neoadjuvant chemoradiotherapy is the standard of care for locally advanced rectal cancer (LARC) to control local recurrence and achieve organ preservation. However, for proficient mismatch repair (pMMR) or microsatellite stable (MSS) LARC, which accounts for nearly 90% of rectal cancers, conventional chemoradiotherapy has limited efficacy and is associated with significant side effects. Recent studies have shown that combining radiotherapy with immunochemotherapy can improve pathological complete response (pCR) rates, but the inclusion of tumor-draining lymph nodes (TDLNs) in the conventional irradiation field may impair T-cell immunity and reduce response to immunotherapy. Our previous single-arm phase II trial demonstrated that node-sparing modified short-course radiotherapy combined with chemotherapy and PD-1 blockade could achieve a high pCR rate of 78.8% in pMMR LARC. 1 Building on these findings, we initiated this phase III trial to compare this new treatment regime with conventional short-course chemoradiotherapy in improving pCR rates. 2 Methods: This is a phase III, open-label, multicenter, randomized trial conducted across 17 hospitals in China. A total of 154 eligible MSS/pMMR middle or low rectal cancer patients (cT3-4N0/+M0) will be recruited and randomly assigned (1:1) to two groups: control group (conventional short-course chemoradiotherapy), experimental group (node-sparing modified short-course chemoradiotherapy plus PD-1 blockade). The innovative node-sparing modified short-course radiotherapy targets only the primary tumor bed, excluding TDLNs. Following randomization, patients will receive short-course radiotherapy (conventional or node-sparing) followed by four cycles of CAPOX ± tislelizumab: tislelizumab 200 mg IV on day 1, oxaliplatin 130 mg/m² IV on day 1, and capecitabine 1000 mg/m² orally on days 1-14, and Total mesorectal excision (TME) will be performed at weeks 14-15. The primary endpoint is pCR rate, while secondary endpoints include organ preservation rate, disease-free survival, overall survival, adverse effects, and quality of life. The primary and secondary endpoints will be analyzed in the intent-to-treat (ITT) population. Safety analyses will be performed in the safety population, defined as patients who received at least one dose of study treatment. Results: 247 patients were assessed for eligibility, a total of 154 patients were enrolled in the ITT population (77 per group). Baseline characteristics were well balanced between the two groups. In the ITT population, the experimental group demonstrated a significantly superior pCR rate compared to the Control group: 61.4% (47/77) vs 28.6% (22/77) (P < 0.001). The MPR rate was also significantly higher in the experimental group (80.5% vs 50.6%). All patients in both groups received sphincter-sparing surgery. Regarding safety, the incidence of grade 3-4 treatment-related adverse events (TRAEs) was comparable between the experimental and control groups (23.4% vs 22.1%). Immune-related adverse events (irAEs) occurred in 7.8% (6/77) of patients in the experimental group, primarily grade 1-2. Conclusions: Compared with conventional short-course preoperative chemoradiotherapy, node-sparing modified radiotherapy combined with CAPOX and PD-1 blockade significantly improved pCR rates in patients with pMMR/MSS LARC, with a manageable safety profile. This regimen represents a promising and highly effective neoadjuvant strategy for MSS rectal cancer. Clinical trial information: NCT06507371. Reference:1. Annals of Oncology (2024) 24 (suppl_1): 1-20. 10.1016/iotech/iotech100744; 2. 2025;43 16_suppl. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3641. Clinical trial information: NCT06507371 .

Detection and countermeasure integrated framework against false data injection attacks in multi-area coupled power systems

Nature Communications Songtao Liu, Lei Xi, Zongze Li et al. Jun 10, 2026 DOI: 10.1038/s41467-026-74374-5

Overcoming Size-Dependent Magnetic Thermal Stability via Atomical Coherence

Journal of the American Chemical Society Ao Chen, Yuting Tang, Zhengdong Cheng et al. Jun 10, 2026 DOI: 10.1021/jacs.6c03129

Genome-wide identification, characterization and expression analysis of the subtilisin-like protease gene family in Quercus ilex in response to Phytophthora cinnamomi

Scientific Reports Daniela M. Hernández, María-Dolores Rey, Mónica Labella-Ortega et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56449-x

Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.

Journal of Clinical Oncology Loubna Outmani, Florian Buisman, Wills Floris Filipe et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba3506

LBA3506 Background: Recurrence after local treatment for colorectal liver metastases (CLM) occurs in up to 70% of patients, frequently confined to the liver. Dutch guidelines do not recommend adjuvant chemotherapy, because three randomized controlled trials (RCTs) have shown no overall survival (OS) benefit of perioperative systemic chemotherapy in resectable CLM. Hepatic arterial infusion pump (HAIP) chemotherapy delivers high doses of floxuridine directly to the liver. This trial evaluated the effectiveness of adjuvant HAIP chemotherapy with floxuridine compared to resection alone in patients with resectable CLM and a low clinical risk score (CRS). Methods: This is an open-label, investigator-initiated, multicenter, randomized phase III trial. Adult patients with resectable CLM, no extrahepatic disease, and CRS 0–2 were randomized 1:1 to resection plus adjuvant HAIP chemotherapy with floxuridine versus resection alone, both without adjuvant systemic chemotherapy. Preoperative systemic chemotherapy prior to randomization was allowed. Patients in both groups who signed informed consent but did not fulfill inclusion criteria at the time of surgery were excluded and replaced. Patients were scheduled for 6 cycles of HAIP chemotherapy with floxuridine (0.12 mg/kg/day) that was initiated 4–12 weeks after placement of a Tricumed constant flow pump. The primary endpoint was progression-free survival (PFS) calculated from the date of surgery to the date of a recurrence or death. Secondary endpoints included hepatic PFS (hPFS) and ninety-day mortality. Survival was estimated using Kaplan-Meier method and compared using a log-rank test. Results: Between August 2018 and March 2026, 243 patients were randomized to resection followed by adjuvant HAIP (n=120) or resection alone (n=123). At time of surgery, 25 patients were excluded due to presence of extrahepatic disease, unresectable CLM or histopathological confirmation of benign disease. In this analyses, 110 patients were included in the resection and adjuvant HAIP group and 108 patients in the resection alone group. In the HAIP group, 100 patients (91%) initiated HAIP chemotherapy, and the median number of administered cycles was 5 [IQR 3-6]. Treatment was discontinued in 8 patients (8%) due to recurrence and in 32 patients (32%) due to toxicity. The median PFS was 15.0 months in HAIP group vs 16.0 months in resection alone group (HR 0.88; 95% CI 0.62–1.25; p=0.48). The median hPFS was 37.6 months in HAIP group vs 21.8 months in resection alone group (HR 0.80; 95% CI 0.54–1.17; p=0.25). Ninety-day postoperative mortality was observed in 4 patients (3.3%) in the HAIP group and in 1 patient (0.8%) after resection alone. No mortality was attributed to pump placement or HAIP chemotherapy. Conclusion: In patients with resectable CLM and a low CRS, no improvement in PFS after adjuvant HAIP chemotherapy with floxuridine compared to resection alone could be demonstrated. Mature results for overall survival are expected in 2029. EudraCT number: 2018-001696-21. Clinical trial information: 2018-001696-21.

Prefrontal parvalbumin neurons mediate working memory in a task demand-dependent manner

Nature Communications Tyler D. Dexter, Meira M. F. Machado, Shahnaza Hamidullah et al. Jun 10, 2026 DOI: 10.1038/s41467-026-73818-2